Skip to main content Accessibility help
×
Home
Hostname: page-component-559fc8cf4f-xbbwl Total loading time: 0.392 Render date: 2021-03-05T03:05:00.252Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Do antipsychotic drugs lose their efficacy for relapse prevention over time?

Published online by Cambridge University Press:  02 January 2018

Stefan Leucht
Affiliation:
Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich, Germany
John M. Davis
Affiliation:
Psychiatric Institute, University of Illinois at Chicago, Chicago, Illinois and Maryland Psychiatric Research Center, Baltimore, Maryland, USA
Rights & Permissions[Opens in a new window]

Summary

There is a debate about long-term treatment of schizophrenia with antipsychotic drugs, with some experts suggesting that these drugs should be discontinued. In this issue, Takeuchi et al demonstrated by a meta-analysis of 11 trials that antipsychotic drugs maintained their efficacy for relapse prevention for 1 year, whereas patients on placebo kept getting worse. We consider these findings in the light of the current discussion about possible dose-related brain volume loss, supersensitivity psychosis, the high variability of results in long-term follow-up studies and recent approaches to discontinue antipsychotics in patients with a first-episode. The new findings speak in favour of continuing antipsychotics at the same dose, at least in patients whose condition is chronic, but the topic is complex.

Type
Editorial
Copyright
Copyright © The Royal College of Psychiatrists 2017 

There is a new debate about long-term treatment with antipsychotics stimulated by data suggesting a dose-related brain volume loss, Reference Huhtaniska, Jaaskelainen, Hirvonen, Remes, Murray and Veijola1 supersensitivity effects of long-term treatment with antipsychotics Reference Chouinard and Jones2,Reference Moncrieff3 and some follow-up studies showing that patients who do not receive antipsychotics in the long-term have better outcomes than treated patients. Reference Harrow, Jobe and Faull4

In this context Takeuchi et al present an analysis of the symptom trajectories in relapse prevention studies over 1 year. Reference Takeuchi, Kantor, Sanches, Fervaha, Agid and Remington5 In the placebo-treated groups they find a continuous worsening of approximately 50% over baseline of the mean Positive and Negative Syndrome Scale (PANSS)/Brief Psychiatric Rating Scale (BPRS) scores at 1 year, compared with an only 10% worsening of these scores in the antipsychotic group. This finding is important because it means that antipsychotic efficacy is maintained over time and should not be discontinued. At first glance, this contrasts with our meta-analysis of relapse prevention studies where 64% of placebo-treated v. 27% of drug-treated patients experienced a relapse within 1 year. Reference Leucht, Tardy, Komossa, Heres, Kissling and Salanti6 When we summarised the relapse rates of only the 11 studies included by Takeuchi et al, the results were more similar 55% v. 22% relapsed. The drug-placebo difference became smaller over time in our analysis, but we discussed that this was likely because of statistical artefacts, among others because most studies did not use survival analyses (Fig. 3 in Leucht et al Reference Leucht, Tardy, Komossa, Heres, Kissling and Salanti6 ). To understand better how it is possible that the average PANSS/BPRS scores remained relatively stable over 1 year on the drug, despite some patients relapsing, one needs to know that in many studies the patients are not necessarily symptom free at baseline and therefore patients can improve, as well as get worse. For example, in Pigott et al 2003, Reference Pigott, Carson, Sana, Torbeyns, Stock and Ingenito7 the average PANSS at baseline was about 82 and at the end-point the drug-treated group improved by two points. Or, in our meta-analysis 30% of drug-treated patients improved at the end-point (Fig. 1 in Leucht et al Reference Leucht, Tardy, Komossa, Heres, Kissling and Salanti6 ). Some patients relapsed in the drug-treated group but this was balanced by those patients that improved.

Supersensitivity psychosis

The symptom trajectories presented by Takeuchi et al are also important in the context of rebound or supersensitivity psychosis, a possibility suggested in the 1970s by Chouinard and colleagues Reference Chouinard and Jones2 based on an observation of ten patients. This is pharmacologically plausible as dopamine supersensitivity is observed in animals. (For reviews, see Murray et al Reference Murray, Quattrone, Natesan, van Os, Nordentoft and Howes8 and Moncrieff. Reference Moncrieff3 ) Takeuchi et al found a gradual worsening of symptoms rather than an initial peak as would be expected for withdrawal symptoms. In our meta-analysis we examined rebound psychosis by comparing abrupt and gradual withdrawal of antipsychotics in the placebo groups, but we did not find any difference. However, the minimum duration of tapering was only 3 weeks, Reference Takeuchi, Kantor, Sanches, Fervaha, Agid and Remington5 which may have been too short. We also compared the relapse rate of drug v. placebo, in patients who were relapse free on either drug or placebo for 3 months, 6 months and 9 months, and then followed up until the end of the studies. The differences in relapse rates between drug and placebo were similar (Fig. 4 in Leucht et al Reference Leucht, Tardy, Komossa, Heres, Kissling and Salanti6 ). If the difference in relapse rates were simply explained by supersensitivity psychosis, the relapse rate should have been lower in those patients who had been relapse free for 9 months. A similar observation has been reported in a meta-analysis of antidepressants. Reference Geddes, Carney, Davies, Furukawa, Kupfer and Frank9 It is possible after some time on the drug that patients might have been ‘cured’, and would not need antipsychotics any longer. In a third analysis we therefore examined whether the drug–placebo difference in relapse rates became smaller in patients who had been stable on antipsychotics for up to 3–6 years before they were randomised to either stay on antipsychotics or to be switched to placebo. We found that even those patients who had been stable for 3–6 years and then were randomised to drug or placebo, those on placebo relapsed at a higher frequency than those who stayed on antipsychotics, and the drug-placebo difference was not influenced by the time patients were stable on antipsychotics before randomisation (Fig. 2 in Leucht et al Reference Leucht, Tardy, Komossa, Heres, Kissling and Salanti6 ). However, the limitation was, again, that drugs were withdrawn abruptly.

Very long-term follow-up

Takeuchi et als data were restricted to 1 year and ours to 2 years, but the very long-term outcome of schizophrenia is complex. Some examples: according to a methodologically sound systematic review on average only 13.5% of patients achieve a full recovery. Reference Jaaskelainen, Juola, Hirvonen, McGrath, Saha and Isohanni10 In contrast, in both studies from the pre-antipsychotic era Reference Aastrup, Fossum and Holmboe11 and in recent studies a considerable proportion of patients with a first psychotic episode were in remission at follow-up, with wide variability in diagnostic criteria, remission criteria and frequency (for example 32% in Aastrup et al, Reference Aastrup, Fossum and Holmboe11 20% in Robinson et al Reference Robinson, Woerner, Alvir, Bilder, Goldman and Geisler12 and 40% in the AESOP study Reference Morgan, Lappin, Heslin, Donoghue, Lomas and Reininghaus13 ). But we cannot identify them in advance and full (social and symptomatic) recovery over a long period may be rare. Reference Jaaskelainen, Juola, Hirvonen, McGrath, Saha and Isohanni10 Harrow et al Reference Harrow, Jobe and Faull4 reported a 20-year follow-up of a Chicago cohort of 70 patients with schizophrenia, drawn in large part from a psychoanalytic hospital, where affluent, mainly first- or second-episode patients, were admitted to hospital for long-term psychoanalysis. In total, 50% (approximately 7 out of 15) of untreated patients compared with about 15% of treated patients were recovered at 20 years. Patients with a better prognosis might not have needed antipsychotics, thus not taking antipsychotics was not necessarily causal for the better outcome (which epidemiologists call ‘confounding by indication’). As an analogy, people who survived a cancer without treatment might also do better than those who underwent chemotherapy. In contrast, at the 14-year follow-up of a well-designed epidemiological study from a defined catchment area in China more untreated patients had died, had higher unemployment rates and fewer were in remission. Reference Ran, Weng, Chan, Chen, Tang and Lin14 Although there are some predictors of non-relapsing patients, they are not accurate enough to be fully confident of correct identification. We would hope that more data on imaging, cognition and genetics will provide robust criteria in the future.

Brain volume loss

The evidence suggesting that antipsychotics cause brain volume loss in a dose-related fashion is worrying, but equivocal, because it is difficult to disentangle whether this is because of the illness or the medication. Higher doses of medication are required for more severely ill patients. In six macaque monkeys olanzapine and haloperidol led to more brain volume loss than placebo. Reference Dorph-Petersen, Pierri, Perel, Sun, Sampson and Lewis15 In an observational 15-year follow-up study higher antipsychotic doses were associated with more brain volume loss, Reference Ho, Andreasen, Ziebell, Pierson and Magnotta16 but in the same sample there was more brain volume loss in those patients who spent most time in exacerbation of psychosis, which would mean that relapses need to be prevented. Reference Andreasen, Liu, Ziebell, Vora and Ho17 Moreover, the clinical relevance is unclear, because in one study treated patients performed better on cognitive tests than untreated patients despite more brain volume loss. Reference Lesh, Tanase, Geib, Niendam, Yoon and Minzenberg18

First-episode studies

The final line of evidence is the open randomised controlled trial by Wunderink and colleagues Reference Wunderink, Nienhuis, Sytema, Slooff, Knegtering and Wiersma19 in which patients in a first-episode in remission were either continued on antipsychotics or were gradually withdrawn. The major difference, in comparison with the classical relapse intervention studies, was that if withdrawal was not possible, medication was reinstituted or the dose re-increased. This strategy is actually quite similar to what many physicians do when following the wishes of their patients. Gradual dose reduction did not prevent relapse in that there were 22% more relapses in the discontinuation group (43%) compared with the continuation group (21%). But most of the 13 patients who could be successfully discontinued initially remained relapse free, and, in the 7-year follow-up patients in the gradual discontinuation group had a significantly better functional outcome. The major limitation was that after the initial 2 years the study was no longer randomised, meaning that patients did not follow the treatment that they had been initially assigned to any longer. Much can have happened in 5 years. This makes it impossible to derive a causal relationship between the initial attempt to withdraw antipsychotics and better functional outcome at 7 years. We find a causal relationship unlikely, in particular because the doses in both groups were similarly low at the end of 2 years (in the attempted withdrawal group 2.8 mg/day haloperidol equivalent and in the maintenance group 2.9 mg/day).

Implications

There have been many attempts to stop medication, closely monitor early warning symptoms of relapse and reinstitute treatment rapidly, but these have failed to prevent relapse. Reference Sampson, Mansour, Maayan, Soares-weiser and Adams20 Attempts to identify the minimum effective doses for relapse prevention with dose-response studies have also proven to be difficult. Reference Kane, Davis, Schooler, Marder, Casey and Brauzer21,Reference Wang, Xiang, Cai, Weng, Bo and Zhao22 But the side-effects of antipsychotic drugs such as movement disorders, sedation, hormonal changes and particularly weight gain can produce significant physical comorbidities that can contribute to the documented excess mortality of schizophrenia. Reference McGrath, Saha, Chant and Welham23 Therefore, an approach to identify the patients with a first-episode who do not need maintenance treatment would solve a major problem. But replications are needed, because the stakes are high when doses are down-titrated with relapse as the lower limit. In the meantime, Takeuchi et al's results speak in favour of continuing antipsychotics at the same dose, at least for chronic illness, because the superiority of antipsychotics compared with placebo was large and increased even further over time.

Footnotes

See pp. 137–143, this issue.

Declaration of interest

In the past 3 years S.L. has received honoraria for consulting from LB Pharma, Lundbeck, Otsuka, Roche, and TEVA, for lectures from AOP Orphan, ICON, Janssen, Lilly, Lundbeck, Otsuka, Sanofi, Roche, and Servier, and for a publication from Roche.

References

1 Huhtaniska, S, Jaaskelainen, E, Hirvonen, N, Remes, J, Murray, GK, Veijola, J, et al. Long-term antipsychotic use and brain changes in schizophrenia – a systematic review and meta-analysis. Hum Psychopharmacol 2017; 32: e2574.CrossRefGoogle ScholarPubMed
2 Chouinard, G, Jones, BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980; 137: 1621.Google ScholarPubMed
3 Moncrieff, J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006; 114: 313.CrossRefGoogle ScholarPubMed
4 Harrow, M, Jobe, TH, Faull, RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med 2012; 42: 2145–55.CrossRefGoogle ScholarPubMed
5 Takeuchi, H, Kantor, N, Sanches, M, Fervaha, G, Agid, O, Remington, G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry 2017; 211: 137143.CrossRefGoogle ScholarPubMed
6 Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Salanti, G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063–71.CrossRefGoogle ScholarPubMed
7 Pigott, TA, Carson, WH, Sana, AR, Torbeyns, AF, Stock, EG, Ingenito, GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048–56.CrossRefGoogle ScholarPubMed
8 Murray, RM, Quattrone, D, Natesan, S, van Os, J, Nordentoft, M, Howes, O, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 2016; 209: 361–5.CrossRefGoogle ScholarPubMed
9 Geddes, JR, Carney, SM, Davies, C, Furukawa, TA, Kupfer, DJ, Frank, E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653–61.CrossRefGoogle ScholarPubMed
10 Jaaskelainen, E, Juola, P, Hirvonen, N, McGrath, JJ, Saha, S, Isohanni, M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39: 1296–306.CrossRefGoogle Scholar
11 Aastrup, C, Fossum, A, Holmboe, R. Prognosis in Functional Psychoses. Clinical, Social and Genetic Aspects. Charles C. Thomas, 1962.Google Scholar
12 Robinson, D, Woerner, MG, Alvir, JM, Bilder, R, Goldman, R, Geisler, S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241–7.CrossRefGoogle ScholarPubMed
13 Morgan, C, Lappin, J, Heslin, M, Donoghue, K, Lomas, B, Reininghaus, U, et al. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 Study. Psychol Med 2014; 44: 2713–26.Google ScholarPubMed
14 Ran, M-S, Weng, X, Chan, CL-W, Chen, EY-H, Tang, C-P, Lin, F-R, et al. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China. Br J Psychiatry 2015; 207: 495500.CrossRefGoogle ScholarPubMed
15 Dorph-Petersen, KA, Pierri, JN, Perel, JM, Sun, Z, Sampson, AR, Lewis, DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30: 1649–61.CrossRefGoogle ScholarPubMed
16 Ho, BC, Andreasen, NC, Ziebell, S, Pierson, R, Magnotta, V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68: 128–37.CrossRefGoogle ScholarPubMed
17 Andreasen, NC, Liu, D, Ziebell, S, Vora, A, Ho, BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170: 609–15.CrossRefGoogle ScholarPubMed
18 Lesh, TA, Tanase, C, Geib, BR, Niendam, TA, Yoon, JH, Minzenberg, MJ, et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiatry 2015; 72: 226–34.CrossRefGoogle ScholarPubMed
19 Wunderink, L, Nienhuis, FJ, Sytema, S, Slooff, CJ, Knegtering, R, Wiersma, D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68: 654–61.CrossRefGoogle ScholarPubMed
20 Sampson, S, Mansour, M, Maayan, N, Soares-weiser, K, Adams, CE. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev 2013; 7: CD006196.Google Scholar
21 Kane, JM, Davis, JM, Schooler, N, Marder, S, Casey, D, Brauzer, B, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159: 554–60.CrossRefGoogle ScholarPubMed
22 Wang, CY, Xiang, YT, Cai, ZJ, Weng, YZ, Bo, QJ, Zhao, JP, et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 2010; 167: 676–85.CrossRefGoogle ScholarPubMed
23 McGrath, J, Saha, S, Chant, D, Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 6776.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 261
Total number of PDF views: 958 *
View data table for this chart

* Views captured on Cambridge Core between 02nd January 2018 - 5th March 2021. This data will be updated every 24 hours.

Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Do antipsychotic drugs lose their efficacy for relapse prevention over time?
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Do antipsychotic drugs lose their efficacy for relapse prevention over time?
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Do antipsychotic drugs lose their efficacy for relapse prevention over time?
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *